» Articles » PMID: 29801989

Ten-year Survival in Glioblastoma. A Systematic Review

Overview
Journal J Clin Neurosci
Specialty Neurology
Date 2018 May 27
PMID 29801989
Citations 160
Authors
Affiliations
Soon will be listed here.
Abstract

Glioblastoma (GBM) is among the most deadly neoplasms associated with one of the worst 5-year overall survival (OS) rates among all human cancers. The aim of this systematic review is to present all cases with OS of a decade or more and to perform a descriptive analysis of the group. This systematic review was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. A comprehensive search for relevant articles was performed on PubMed, Embase and Google Scholar for a period until June 10, 2016, using the following search words: glioblastoma multiforme, glioblastoma, GBM, long-term survival/survivors. Reports containing cases with the long-term survival of 10 years or longer were included in the review. The search produced 36 studies with 162 cases published in the years 1950-2014. The rate of long survivors in the cohort studied was established 0.76%. Mean age at diagnosis, OS and PFS were 31.1 ± 11.1, 15.9 ± 6.3, 11.9 ± 5.6 years respectively. Total and subtotal resections were found in 82 and 58 patients respectively. Nine cases received a biopsy alone. No statistical differences were found in a comparison of PFS, OS and age between total and subtotal resection groups. A regression analysis showed a significant correlation between PFS and OS, with an inverse relationship stated between age at diagnosis and OS. The 10-year survival rate in the cohort studied with GBM was estimated 0.71%. OS was positively correlated with the length of PFS and inversely related with age at diagnosis.

Citing Articles

Expression Drives Sensitivity to the Antibody-Drug Conjugate Tisotumab Vedotin in Glioblastoma.

Sears T, Wang W, Drumm M, Unruh D, McCord M, Horbinski C Cancers (Basel). 2025; 17(5).

PMID: 40075681 PMC: 11898980. DOI: 10.3390/cancers17050834.


Unscheduled hospitalization as a potential trigger for specialist palliative care referral in patients with high grade glioma: a retrospective analysis in a tertiary hospital.

Torres-Tenor J, Garcia-Leal A, Hui D, Bruera E, Martinez-Marin V, Castano-Cantos A J Neurooncol. 2025; .

PMID: 40048038 DOI: 10.1007/s11060-025-04993-3.


Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.

Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A Mol Cancer. 2025; 24(1):58.

PMID: 40011944 PMC: 11863469. DOI: 10.1186/s12943-025-02267-0.


Response Assessment in Long-Term Glioblastoma Survivors Using a Multiparametric MRI-Based Prediction Model.

de Godoy L, Rajan A, Banihashemi A, Patel T, Desai A, Bagley S Brain Sci. 2025; 15(2).

PMID: 40002479 PMC: 11852837. DOI: 10.3390/brainsci15020146.


Innovative perspectives on glioblastoma: the emerging role of long non-coding RNAs.

Doghish A, Mahmoud A, Abd-Elmawla M, Zaki M, Aborehab N, Hatawsh A Funct Integr Genomics. 2025; 25(1):43.

PMID: 39992471 DOI: 10.1007/s10142-025-01557-6.